Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab

February 13, 2023

Colombo et al • 2022 • International Gynecologic Cancer Society 2022 Annual Meeting

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

February 11, 2023

Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

February 9, 2023

Munster et al • 2022 • Clin Cancer Res OF1–OF11

A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

February 5, 2023

Borazanci et al • 2022 • American Society of Clinical Oncology Annual Meeting

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells

January 26, 2023

Greenstein et al. • 2021 • Oncotarget . 2021 Jun 22;12(13):1243-1255. doi: 10.18632/oncotarget.27989.